Similar articles

• [Potential risk and benefit of the combination of trastuzumab to chemotherapy and radiation therapy in non-metastatic breast cancer].

  Belkacémi Y, Laharie-Mineur H, Gligorov J, Azria D. Belkacémi Y, et al. Cancer Radiother. 2007 Sep;11(5):266-75. doi: 10.1016/j.canrad.2007.04.002. Epub 2007 Jul 20. Cancer Radiother. 2007. PMID: 17644449 Review. French.
• Tomorrow's targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity?

  Magné N, Chargari C, MacDermed D, Conforti R, Védrine L, Spano JP, Khayat D. Magné N, et al. Crit Rev Oncol Hematol. 2010 Dec;76(3):186-95. doi: 10.1016/j.critrevonc.2010.01.012. Epub 2010 Feb 6. Crit Rev Oncol Hematol. 2010. PMID: 20138541 Review.
• Reversibility of trastuzumab cardiotoxicity: is the concept alive and well?

  Ewer MS, Tan-Chiu E. Ewer MS, et al. J Clin Oncol. 2007 Dec 1;25(34):5532-3; author reply 5533-4. doi: 10.1200/JCO.2007.14.0657. J Clin Oncol. 2007. PMID: 18048835 No abstract available.
• Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study.

  Shaffer R, Tyldesley S, Rolles M, Chia S, Mohamed I. Shaffer R, et al. Radiother Oncol. 2009 Jan;90(1):122-6. doi: 10.1016/j.radonc.2008.09.003. Epub 2008 Oct 29. Radiother Oncol. 2009. PMID: 18976826
• [Cardioprotective treatment during adjuvant cancer therapy].

  Gulati G, Heck SL, Ree AH, Gravdehaug B, Røsjø H, Steine K, Bratland Å, Hoffmann P, Geisler J, Omland T. Gulati G, et al. Tidsskr Nor Laegeforen. 2013 Sep 17;133(17):1832-6. doi: 10.4045/tidsskr.12.1514. Tidsskr Nor Laegeforen. 2013. PMID: 24042297 Review. Norwegian.